national patent development corp. said 0 it plans to purchase as many as 200,000 common shares of its 81%-controlled interferon sciences inc. unit in periodic , open-market purchases . the 200,000 shares are about 23 % of interferon 's common shares outstanding , excluding national patent 's stake . noting the recent food and drug administration approval of interferon 's genital warts treatment , national patent said 0 it believes 0 interferon 's stock is undervalued .